Abstract: A multilayer scintillation detector, includes at least three layers superposed on one another, and each extending parallel to a plane, called the detection plane, wherein each layer is formed by a first material, called a scintillation material, capable of interacting with an ionizing radiation and of forming, following the interaction, a scintillation light in a scintillation spectral band; each layer has a plurality of light guides, respectively extending parallel to the detection plane, according to a length, the light guides being disposed, over all or part of their length, parallel to an axis of orientation; the axis of orientation of the light guides of each layer is oriented, in the detection plane, according to an orientation, the orientations of the respective axes of orientation of at least three layers being different from one another, such that each layer has an associated orientation; and the scintillation material has a first refractive index.

Abstract: The present invention relates to a process for determining in vitro the immune status of an individual according to which: (a) a blood sample from the individual is provided, (b) at least two reagents specific to at least two products of expression of at least two target genes are provided; (c) the expression of said at least two target genes is determined, and (d) the expression of said at least two target genes respectively is compared with a reference expression, with a change in the expression of said at least two target genes relative to their reference expression indicating that the individual's immune status has changed, and a correlation between the expression of said at least two target genes with their reference expression indicating that the individual's immune status is normal; as well as a kit for determining said immune status of the individual.

Abstract: The disclosure relates to benzoimidazole derivatives, acting as anticancer drugs, as well as pharmaceutical composition containing said compounds. These compounds are able to firstly inhibit the protein/protein interactions of the MAP Kinase Erk, leading to inhibition of proliferation and secondly to induce apoptosis in human cancer cell lines.

Abstract: A method for determining in vitro or ex vivo the immune status of an individual, preferably a patient, including a step of detecting and/or quantifying the expression of one or more HERV/MaLR sequences in a biological sample of the individual. Also relates to the tools for implementing the method and to the uses thereof.

Abstract: The invention relates to an in vitro process for determining the functional IL-17 pro-inflammatory dependent level (IPDL) of a biological sample, comprising the following steps: a) measuring the level of an inflammatory marker produced by IL-17-sensitive cells incubated in the presence of a biological sample, b) measuring the level of said inflammatory marker produced by said cells incubated in the presence of a biological sample, in the presence of antibodies which neutralize the biological activity of IL-17, and c) determining the IPDL level, which is the difference between the level of said inflammatory marker measured in step a) and the level of said inflammatory marker measured in step b).

Abstract: The present invention relates to a pharmaceutical combination product comprising: a liposomal formulation exclusively containing a LPS; and at least one cytotoxic compound. It also relates to its use as an anti-tumour therapy.

Abstract: A method for estimating the affinity ? of a first DNA strand, or “probe”, to be hybridized with a second DNA strand, or “target”, to form a hybrid of length Lbp, the method comprising: in each division of a set of M divisions of the hybrid, counting the number of times in which each hybrid of a set of P DNA strand hybrids is present in the division, the hybrids being of length k less than the length Lbp, or “k-hybrids”; for each combination of mismatches of a set of L combinations of mismatches in a hybrid of length Lbp, determining whether the pair of mismatches is present in the hybrid; and calculating the affinity ? according to the relation: ? = ? m = 1 M ? ? p = 1 P ? x m , p · ? ^ m , p + ? .

Abstract: The present invention relates to a non-implantable medical device (1, 1?) intended to cover wounds and skin lesions, comprising a biosensor (3E, 3E?), characterised in that said biosensor (3E, 3E?) comprises a piece made of absorbent, hydrophilic material fixing, on the surface and/or within the thickness thereof, a composition of agglomerated powders comprising particles of ethylene vinyl acetate (EVA) having a surface in part covered with at least one orthophosphoric acid salt and a visual indicator of microbiological growth. In particular, the medical device (1, 1?) may comprise several layers in order to enable the guiding of a liquid. The present invention relates to a method for preparing such a medical device (1, 1?).

Abstract: A kit for in vitro or ex vivo measurement of the expression of solubleCD127 in a biological sample, including: tools or reagents for measuring the expression of solubleCD127 in the biological sample; and a positive control sample, which is a sample calibrated to contain the quantity of sCD127 that corresponds to the mean quantity measured in a pool of samples from patients who have been subjected to an insult or to an infection generating a systemic inflammatory response who are known to have survived, and/or a negative control sample, which is a sample calibrated to contain the quantity of solubleCD127 that corresponds to the mean quantity measured in a pool of samples from patients who have been subjected to an insult or to an infection generating a systemic inflammatory response who are known not to have survived.

Abstract: The present invention relates to a method for diagnosing anomalies in the coagulation of blood, comprising the following successive steps: a) placing a sample of total blood in a holder containing two pairs of electrodes connected to an apparatus generating an electrical current; b) incubating this sample for 60 to 180 seconds in the presence of calcium; c) adding to this sample tissue factor in a concentration high enough to trigger the coagulation of the blood; d) measuring the impedance variation between the electrodes as a function of time, for a period comprised between 10 and 30 minutes from step (c), and generating a curve of the impedance values as a function of time; e) comparing the value of the area under the curve generated in step (d) with the value of an area under a reference curve.

Abstract: A kit for in vitro or ex vivo measurement of sCD127 expression in a biological sample, the kit including: specific tools or reagents allowing measurement of sCD127 expression in said biological sample; and a positive standard sample which is a sample calibrated to contain an amount of sCD127 which corresponds to the mean amount measured in a pool of samples from patients who are known to have developed a nosocomial infection, and/or a negative standard sample which is a sample calibrated to contain the amount of sCD127 which corresponds to the mean amount measured in a pool of samples from patients who are known not to have developed a nosocomial infection.

Abstract: The invention provides a method of evaluating the risk of mortality in patients who present a systemic inflammatory response (SIRS) or septic syndromes, comprising measuring the expression of sCD127 in a biological sample.

Abstract: Dendronized metallic oxide nanoparticles, a process for preparing the same and their uses.

Abstract: The present invention relates to biofunctionalized nanoparticles and uses thereof in adoptive cell therapy. In particular, the present invention relates to a nanoparticle comprising an amount of at least one antigen and an amount of at least one antibody having specificity for a B cell receptor wherein the antigen and antibody are attached to the surface of the nanoparticle.

Abstract: The present invention relates to the diagnosis of acquired sensory neuronopathies (SNN), and to the treatment of these disorders.

Abstract: The present disclosure relates to a human CK8 antigen peptide, an antibody, or antibody fragment thereof, or a humanized antibody, specifically binding the peptide having the amino acid sequence of SEQ ID No. 29, a fragment of CK-8. Said molecules can be used use in the detection and/or treatment of tumors whose cells express CK8 protein, in particular the peptide of sequence according to SEQ ID No.29, on their surface.

Abstract: A method for predicting the risk of developing a disseminated infection in a patient admitted to intensive care having no clinical symptoms of such infection includes: determining a first dose of gelsolin G1 in a biological sample from the patient originating from a first sample taken at time T1, carried out between the day of intensive care admission and 48 hours afterward; determining a second dose of gelsolin G2 in a biological sample from the patient originating from a second sample taken at time T2, carried out two to three days after the first sampling; calculating the variation between the dose of gelsolin G2 and the dose of gelsolin G1, giving a ? value; and comparing the ? value to a threshold value S determined beforehand from two patient populations admitted to intensive care, one not having developed a disseminated infection and the other having developed such an infection.

Abstract: The present invention relates to a viral vector for expression of the cell death-inducing PUMA protein, for use in gene therapy, for example for the treatment of rheumatoid arthritis. This vector consists in particular of a recombinant adenovirus expressing the gene encoding the PUMA protein and of a recombinant baculovirus containing a coxsackie-adenovirus receptor (CAR).

Abstract: A method of evaluating the effectiveness of an auditory prosthesis comprises transmitting a stimulus via an auditory prosthesis, thereby delivering an auditory stimulus to the auditory nervous system of a person fitted with said auditory prosthesis, picking up the neurophysiological signals transmitted by said auditory nervous system in response to the auditory stimulus by means of an electro- or magneto-encephalography system, and processing the received signals. The method also includes transmitting a stimulus made up of at least one pair of linguistic units selected from a phonetic confusion matrix, picking up a neurophysiological signal in response separately for each linguistic unit, and comparing the signals in order to evaluate the effectiveness of the prosthesis.

Abstract: The present invention relates to the use of at least one biomarker for predicting the severity of a disease caused by the infection of an individual with an influenza virus, wherein said biomarker is selected in a group comprising (i) the alpha diversity value of the microbiome present in a respiratory sample of said individual and (ii) the microbiome profile of the said respiratory sample.